Craig Hallum downgraded CareDx from Buy to Hold and set a new price target of $9.00 from $26.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/15/2025 | $28.00 → $24.00 | Underweight → Equal Weight | Wells Fargo |
| 8/28/2024 | $28.00 | Underweight | Wells Fargo |
| 8/19/2024 | $40.00 | Neutral → Buy | BTIG Research |
| 5/13/2024 | Outperform → Mkt Perform | Raymond James | |
| 5/1/2024 | $15.00 | Hold → Buy | Craig Hallum |
| 11/9/2023 | $10.00 | Equal-Weight → Overweight | Stephens |
| 8/15/2023 | $12.00 | Mkt Perform → Outperform | Raymond James |
| 5/11/2023 | Buy → Neutral | BTIG Research |
4 - CareDx, Inc. (0001217234) (Issuer)
4 - CareDx, Inc. (0001217234) (Issuer)
4 - CareDx, Inc. (0001217234) (Issuer)
8-K - CareDx, Inc. (0001217234) (Filer)
SCHEDULE 13G/A - CareDx, Inc. (0001217234) (Subject)
8-K - CareDx, Inc. (0001217234) (Filer)
Fourth Quarter Revenue is Expected to Increase 30% Year-Over-Year Expects Full Year 2024 Revenue of $332 Million to $333 Million CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ – today reported preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2024. Preliminary Fourth Quarter 2024 Financial Results Revenue is expected to be between $85 million and $86 million, an increase of approximately 30% year-over-year. Testing services revenue is expected to be between $62.5 million and $63.5 million, an increase of approximately 35% year-over-year. Testing Services volume of approximately 45,500 increased 14% year-over-year. Revenu
CareDx, Inc. (NASDAQ:CDNA) - The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that the company will participate in the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. CareDx's management is scheduled to present on Tuesday, January 14, 2025, at 4:30 p.m. Pacific Time (7:30 p.m Eastern Time). To listen to the webcast, please visit the Events & Presentations section of CareDx's Investor Relations website at: investors.caredx.com. About CareDx – The Transplant Company CareD
CareDx Continues Strategic Expansion into Hematology Oncology with Pharmacokinetic and Monitoring Assays for Cell Therapy Patients CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that CareDx will partner with TC BioPharm to perform pharmacokinetic analysis using its AlloCell™ solution in the ACHIEVE clinical trial. AlloCell has been used in ten prior cell therapy clinical trials and with the addition of the ACHIEVE trial is being actively used in four clinical trials
Third Quarter 2024 Financial Results to be Reported on November 4, 2024 CareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers —today reported preliminary financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Highlights Third quarter revenue is expected to be in the range of $82 million to $83 million, an increase of approximately 23% year-over-year. Grew Testing Services volume to approximately 44,600, an increase of approximately 16% year-over-year. Testi
CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the second quarter 2024 after market close on Wednesday, July 31, 2024. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing 1-800-267-6316 for domestic callers or 1-203-518-9783 for international callers. Please reference Conference ID: CareDx. To listen to a live webcast, pl
CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the first quarter 2024 after market close on Thursday, May 9, 2024. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing 1-800-343-4136 for domestic callers or 1-203-518-9843 for international callers. Please reference Conference ID: CareDx. To listen to a live webcast, please
SC 13G/A - CareDx, Inc. (0001217234) (Subject)
SC 13G/A - CareDx, Inc. (0001217234) (Subject)
SC 13G/A - CareDx, Inc. (0001217234) (Subject)
CareDx, Inc. (NASDAQ:CDNA)- The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the appointment of Jing Huang Ph.D., in the newly created role of Chief Data and Artificial Intelligence (AI) Officer. Huang will lead key data science initiatives that are a part of the Company's long-term strategic growth plan. CareDx intends to share its long-term growth strategy during an Investor Day on October 15, 2024. Huang is a recognized leader in data science and machine learning, bringing to CareDx a proven trac
CareDx Announces Addition of Operational and Commercial Expertise to Lead Key Strategic Initiatives Marica Grskovic Appointed Chief Strategy Officer to Lead Corporate Development CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the appointment of two senior executives who will lead key initiatives as the Company advances its long-term strategic growth plan. CareDx will be sharing its long-term growth strategy during an Investor Day in October 2024. Keith Kennedy brings more than 20 years of experience and e
CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – has appointed John W. Hanna as its new President and Chief Executive Officer, and member of the Company's Board of Directors, effective April 15, 2024. "John is an outstanding leader with a proven track record of building high-performing teams that deliver consistent results. With extensive experience in the molecular diagnostics and life sciences tools industries, John is the right executive to bring strategic leadership to CareDx to propel the compan
Wells Fargo upgraded CareDx from Underweight to Equal Weight and set a new price target of $24.00 from $28.00 previously
Wells Fargo initiated coverage of CareDx with a rating of Underweight and set a new price target of $28.00
BTIG Research upgraded CareDx from Neutral to Buy and set a new price target of $40.00